Saturday, July 11, 2026

Drug profile · INN

levopropoxyphene napsylate anhydrous

levopropoxyphene napsylate anhydrous (NOVRAD) is a unknown. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — levopropoxyphene napsylate anhydrous
US status
approved
Class
Route
ORAL
Patents
0
Programs
0
Data quality
0.84

Quick answer

levopropoxyphene napsylate anhydrous (NOVRAD) is a unknown. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN levopropoxyphene napsylate anhydrous
Brand NOVRAD
Mechanism Unknown
Route ORAL
Formulation CAPSULE

Mechanism of action

Unknown

Approval history

Authority Status Date
FDA approved

Frequently asked questions

What is levopropoxyphene napsylate anhydrous?

levopropoxyphene napsylate anhydrous (NOVRAD) is a unknown. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for levopropoxyphene napsylate anhydrous?

NOVRAD is a marketed brand name for levopropoxyphene napsylate anhydrous. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of levopropoxyphene napsylate anhydrous?

levopropoxyphene napsylate anhydrous has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.